FUJIFILM SILVAMP TB-LAM (FujiLAM) is a rapid highly sensitive urine-based point-of-care TB diagnosis kit that detects low concentrations of LAM-antigen in the urine of people with TB/HIV co-infection.

By applying FUJIFILM’s unique silver halide amplification technology, the kit allows to amplify the virus marker included in the collective specimen to increase its size, greatly increasing the visibility of the marker. This breakthrough technology is inexpensive, highly sensitive, and does not require large equipment or a power supply to operate, so it can be utilized in resource-limited settings in low- and middle-income countries.

Preliminary data was generated by testing retrospectively banked samples and it was found that FujiLAM clinical sensitivity across TB HIV+ patients was 71% compared to 35% for the current commercial LAM test. The FujiLAM assay is currently undergoing multicenter clinical trials in many countries to assess performance in various settings and indications for use to obtain WHO endorsement.